Skip to main content

ETVAX – the first oral vaccine for protection against traveller’s diarrhoea caused by ETEC

Periodic Reporting for period 1 - ETVAX (ETVAX – the first oral vaccine for protection against traveller’s diarrhoea caused by ETEC)

Reporting period: 2017-06-01 to 2018-08-31

Travellers’ Diarrhoea (TD) caused by enterotoxigenic E. coli bacteria is the most common illness that affects travellers traveling in the developing regions. Currently, there is no approved method for preventing TD. Travellers are recommended to use off-label antibiotics such as Rifaximin or the cholera vaccine Dukoral to prevent TD. In business terms, there exists a strong business opportunity in developing and commercializing an effective and safe ETEC vaccine. Scandinavian Biopharma is the first SME positioned to capture this opportunity.
Scandinavian Biopharma is developing ETVAX – an oral vaccine against traveller’s diarrhoea caused by enterotoxigenic E. coli bacteria (ETEC). ETVAX has a strong potential to be the first vaccine with a full ETEC indication. The development of the vaccine is run in collaboration with the world’s most prominent experts in ETEC vaccine research (e.g. professor Ann-Mari Svennerholm and Professor Jan Holmgren, Göteborg University, Dr Louis Bourgeois, PATH and Professor Anu Kantele, University of Helsinki.).

The Phase IIb study at the core of the project will allow Scandinavian Biopharma to progress towards commercialization of ETVAX.
The project is progressing according to plan. The study started in July 2017 and more than 494 travellers have been vaccinated in Finland and travelled to Grand Popo in Benin to participate in the study. As the project is complex and includes organizations from several different countries, Scandinavian Biopharma invests a lot of effort into co-ordination, communication and dissemination activities. The project has already attracted major media attention as well as scientific attention and World Health Organization is following the project closely.
The project delivers an ultimate EU added value by offering the first ETEC vaccine with proven immunogenicity, safety and efficacy. From the scientific perspective, this means that the project fills the gap in the vaccine research on the EU and global level as no other efficient methods for prevention of TD have been proposed on the market to date. The introduction of ETVAX will ultimately decrease number of TD cases among travellers, decrease number of patients with irritable bowel syndrome or other chronic diseases connected to TD, as well as decrease healthcare costs and productivity losses on the EU level. If successfully validated and accepted by regulatory bodies, ETVAX will take Scandinavian Biopharma to a new level of competitiveness and growth.